Existing strategies to enhance peptide immunogenicity for cancer vaccination generally require direct peptide alteration, which, beyond practical issues, may impact peptide presentation and result in vaccine variability. Here, we report a simple adsorption approach using polyethyleneimine (PEI) in a mesoporous silica microrod (MSR) vaccine to enhance antigen immunogenicity. The MSR-PEI vaccine significantly enhanced host dendritic cell activation and T-cell response over the existing MSR vaccine and bolus vaccine formulations. Impressively, a single injection of the MSR-PEI vaccine using an E7 peptide completely eradicated large, established TC-1 tumours in about 80% of mice and generated immunological memory. When immunized with a pool of B16F10 or CT26 neoantigens, the MSR-PEI vaccine eradicated established lung metastases, controlled tumour growth and synergized with anti-CTLA4 therapy. Our findings from three independent tumour models suggest that the MSR-PEI vaccine approach may serve as a facile and powerful multi-antigen platform to enable robust personalized cancer vaccination.
Cancer vaccines targeting multiple tumour-specific antigens can elicit broad immune responses and decrease tumour escape 1, 2 , and recent advances enable identification of tumour-specific mutations ('neoantigens') 3, 4 . Neoantigens are attractive vaccine targets as they are not expressed in healthy tissues and are predicted to have strong major histocompatibility complex (MHC)-binding affinity 5 . Recent clinical data have shown that neoantigen vaccines could generate T cells that specifically target heterogeneous tumour clones 6 . However, neoantigen peptides exhibit rapid clearance and low immunogenicity, which limits optimal presentation by antigenpresenting cells to initiate strong T-cell responses 7 . Macro-and nano-engineering strategies have been designed to overcome these challenges [8] [9] [10] [11] , but many approaches require chemical modification or physical emulsification of the peptides, potentially altering their presentation capacity. Moreover, since neoantigen vaccines typically require many peptides 12 , modification of individual peptides is cumbersome for clinical translation and is likely to result in high batch-to-batch variability.
We propose a facile strategy to enhance antigen immunogenicity using polyethyleneimine (PEI) combined with a mesoporous silica microrod (MSR) vaccine. The MSR vaccine can be injected using standard needles, was shown to effectively concentrate and activate large populations of host antigen-presenting cells and induced more potent humoral responses and prophylactic tumour protection than traditional vaccine formulations 13 . Moreover, the MSR surface could potentially be modified to induce stronger responses. Recent studies have shown that complexes based on PEI, a widely used cationic polymer 14, 15 , can stimulate pro-inflammatory cytokine production 16, 17 , and induce potent humoral responses when complexed with glycoproteins 18 . Here, we explore the application of PEI to co-present an antigen in a facile, layered adsorption manner in the MSR vaccine.
MSRs were adsorbed with PEI (MSR-PEI) by simply mixing with a PEI solution for 15 minutes; subsequently, an antigen pool was directly adsorbed onto MSR-PEI particles (Fig. 1a ). Both relative molecular mass 60,000 (60K) branched PEI (B60K) and 25K linear PEI (L25K) absorbed to MSR with high efficiency (Fig. 1b) , with an incorporation capacity of about 20 μ g PEI per mg MSR. Over 90% of B60K and L25K PEI polymers were adsorbed after 1 min of mixing ( Fig. 1c ). Zeta potential measurements confirmed PEI incorporation (Fig. 1d ). MSR-PEIs maintained the intrinsic mesopores of MSRs ( Supplementary Fig. 1a ), pore structure and bulk particle structure ( Supplementary Fig. 1b-d) , with reduced surface area and pore volume as expected ( Supplementary Table 1 ). MSRs and MSR-PEIs showed high incorporation efficiency for net positive and neutral example murine ( Fig. 1e ) and human ( Fig. 1f) peptides, but MSR-PEI enhanced the incorporation of net negative peptides.
The underlying adjuvant effect of PEI 19, 20 on bone-marrowderived dendritic cells (BMDCs) was next examined. BMDCs take up free PEI, reaching maximum uptake at 24 h ( Supplementary Fig. 2a ), and showed a significant increase in CD86 and MHC-II expression ( Fig. 1f ) and tumour necrosis factor α (TNF-α ) ( Fig. 1g ) and interleukin-6 (IL-6) ( Fig. 1h ) production in a PEI dose-dependent manner. BMDCs stimulated with MSR-PEI also showed significantly increased CD86 expression ( Supplementary Fig. 2b ) and TNF-α production ( Supplementary Fig. 2c ). MSR-PEI also triggered the increased production of IL-1β , a key cytokine produced in response to Nlrp3 inflammasome activation 21 ( Supplementary Fig. 3a ). This was probably a result of lysosomal rupture upon MSR-PEI uptake ( Supplementary Fig. 3b ), leading to the release of phagosomal contents into the cytosolic compartment. Interestingly, as TNF-α and IL-6 have been shown to be Nlrp3-independent cytokines 22 , it is possible that MSR-PEI particles can stimulate multiple damageassociated molecular pattern (DAMP) receptors. The impact of PEI Letters NATuRE MATERIALS on antigen presentation was next examined by pulsing BMDCs with ovalbumin (OVA) either alone or together with B60K PEI for 2 days. B60K PEI led to an approximately 10-to 20-fold increase in antigen cross-presentation when compared with OVA alone (Fig. 1i ). Finally, as the MSRs and PEI solutions were endotoxin free (Supplementary Table 2 ), and BMDC activation was unaffected by TLR4 neutralization ( Supplementary Fig. 4 ), the activation of DCs was probably not a result of material contamination. Together, these data suggest that PEI can be efficiently and easily incorporated into MSRs, that a broad range of neoantigen peptides can be subsequently incorporated via adsorption and that PEI and MSR-PEI particles can enhance DC activation and cross-presentation.
The ability of an MSR-PEI vaccine to improve DC activation in vivo was then analysed by comparing the MSR vaccine incorporating granulocyte-macrophage colony-stimulating factor (GM-CSF) to recruit host DCs, the TLR-9 agonist CpG-ODN and a model antigen OVA as previously described 13 with the MSR-PEI vaccine incorporating these agents ( Fig. 2a ). In vitro, GM-CSF and PEI were released in a sustained manner from the MSR-PEI vaccine, while CpG was rapidly released due to its negative charge ( Supplementary Fig. 5 ). Mice were immunized with the MSR vaccine (V) or the MSR-PEI vaccine (VP). In both vaccines, CpG-ODN was incorporated, as TLR-9 activation can efficiently induce a type 1 and CD8 killer T-cell (CTL) response 23 . The total numbers of cells recruited to the vaccine on day 3 were comparable between V and VP immunized mice ( Fig. 2b ). However, VP showed a significant enrichment of CD11c + CD86 + activated DCs (Fig. 2c ), CD11c + CCR7 + LN homing DCs ( Fig. 2d ) and CD11c + SIINFEKL-H2K b+ antigen cross-presenting DCs (Fig.  2e ). The vaccine draining lymph node (dLN) total cellularities . c, Incorporation kinetics of soluble B60K and L25K PEI into MSRs (representative data, repeated at least three times). d, Zeta potential of MSR-PEI particles using various doses of soluble B60K and L25K PEI (n = 3). e,f, Incorporation efficiency of murine (e) and human (f) neoantigen peptides (colour-codedaccording to the net charge at neutral pH) onto bare MSR or MSR-PEI particles using B60K PEI (n = 3, two-tailed t-test). g, Flow cytometry analysis of CD86 and MHC-II expression on murine BMDCs after 24 h of stimulation with 1 μ g or 7 μ g of soluble PEI or PBS (n = 4, compared with PBS by one-way analysis of variance (ANOVA)). h,i, Enzyme-linked immunosorbent assay (ELISA) analysis of TNF-α (h) and IL-6 (i) concentration in murine BMDC supernatant after 24 h of stimulation with 1 μ g or 7 μ g of soluble B60K and L25K PEI or PBS (n = 4, compared with PBS by one-way ANOVA). j, Flow cytometry analysis of SIINFEKLpresenting murine BMDCs after stimulation with PBS, OVA, and OVA with 5 μ g or 10 μ g of soluble B60K PEI (n = 3, compared with OVA by one-way ANOVA). Data depict mean ± s.d.
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NATuRE MATERIALS between V and VP immunized mice were similar on day 3, but VP immunized mice showed strikingly higher dLN cellularity on day 5 ( Fig. 2f ). Additionally, VP elicited a strong enrichment in activated DCs ( Fig. 2g and Supplementary Fig. 6a ) and antigenpresenting DCs (Fig. 2h ), but not in the macrophage populations ( Supplementary Fig. 6b ,c) in the dLN. Next, the impact of a direct association between antigen and PEI was evaluated. While maintaining a constant dose of GM-CSF, CpG, OVA and PEI, two types of VP vaccine were tested: (1) a trans form (trans VP) that combined CpG adsorbed onto MSR-PEIs, OVA adsorbed onto bare MSRs and GM-CSF adsorbed onto also bare MSRs, or (2) a cis form (cis VP) that combined OVA adsorbed onto MSR-PEIs, CpG adsorbed on to bare MSRs and GM-CSF adsorbed onto also bare MSRs (Fig. 2i ). The incorporation efficiencies of GM-CSF, CpG and OVA were comparable (Supplementary Table 3 ). The cis VP vaccine showed twice as many activated DCs in the scaffold ( Fig.  2j ) and three times as many activated and antigen-presenting DCs in the dLN (Fig. 2k ,l) when compared with the trans VP vaccine. The myeloid cell population in the scaffold was not impacted ( Supplementary Fig. 6d ). Collectively, these data demonstrate that the MSR-PEI vaccine enhanced host DC activation, antigen presentation and trafficking to secondary lymphoid organs. The ability of the MSR-PEI vaccine to induce a CTL response with the model antigen OVA was next examined. Circulating peripheral blood mononuclear cells (PBMCs) were analysed 7 days after immunization with V or VP vaccines. Mice immunized with VP generated about twice as many circulating IFN-γ + (Fig. 3a ) and tetramer + (Fig. 3b ) CTLs when compared with V. Furthermore, effector T cells outnumbered regulatory T cells by about 15-fold at the VP vaccine site, almost three times higher than at the V vaccine site ( Fig. 3c ). Increasing the PEI dose in VP to above 40 μ g per vaccine led to a decrease in CTL responses ( Fig. 3d ). Similarly to VP using B60K PEI, the VP formulation using L25K PEI also showed an enhanced CTL response when compared with V ( Fig. 3e ). No significant differences were observed when varying PEI structure and molecular weight ( Supplementary Fig. 7a ). Finally, and consistent with our previous finding on host DC activity, a cis VP vaccine showed a significantly higher CTL response when compared with a trans VP vaccine and the MSR vaccine ( Fig. 3f ). To exclude the possibility that a higher dose of PEI in the trans VP vaccine may c-e, Total number of CD11c + CD86 + activated DCs (n = 4, two-tailed t-test) (c), CD11c + CCR7 + LN homing DCs (n = 4, two-tailed t-test) (d) and SIINFEKL-presenting DCs (n = 4, two-tailed t-test) (e) recruited to the vaccine site on day 3 after immunization with V or VP using B60K PEI. f-h, Total number of cells (n = 4 for day 3 and n = 5 for day 5, two-way ANOVA) (f), of CD11c + CD86 + or CD11c + MHC-II + activated DCs (n = 4 for day 3 and n = 5 for day 5, two-way ANOVA) (g) and OVA + DCs (n = 4 for day 3 and n = 5 for day 5, two-way ANOVA) (h) in the dLN on days 3 and 5 after immunization with V or VP using B60K PEI or left unimmunized (N). i, Schematic representations of the MSR-PEI trans vaccine (trans VP) and the MSR-PEI cis vaccine (cis VP). j, Total number of CD11c + CD86 + activated DCs at the vaccine site on day 3 after immunization with the trans VP vaccine or the cis VP vaccine (n = 5, two-tailed t-test). k,l, Total number of CD11c + CD86 + activated DCs (k) and CD11c + OVA + DCs (l) in the dLN on day 5 after immunization with the trans VP vaccine or the cis VP vaccine (n = 5, two-tailed t-test). Data depict mean ± s.d.
NATuRE MATERIALS improve the response, two increasing doses of PEI in the trans VP vaccine were evaluated, and the CTL response decreased with increasing PEI ( Supplementary Fig. 7b ).
To test whether the MSR-PEI vaccine may induce anti-tumour immunity against tumour-specific peptides, a synthetic long peptide derived from the E7 oncoprotein of human papilloma virus (HPV) was used as the antigen. Beyond cervical cancer, HPV is associated with 30-60% of oropharyngeal, vaginal and head-andneck cancers [24] [25] [26] . Consistent with our findings using OVA antigen, VP induced about two to three times higher E7-specific IFN-γ + (Fig. 4a ) and tetramer + (Fig. 4b) circulating CTLs when compared with V. Mice immunized with VP showed significantly elevated blood TNF-α levels ( Fig. 4c ). Next, mice were inoculated with E7-expressing TC-1 carcinoma subcutaneously and treated with a single injection of V or VP when tumour areas reached about 25 mm. VP triggered rapid and complete regression in a majority of the animals, whereas V induced only partial regression ( Fig. 4d ). Importantly, VP led to complete regression of even tumours that reached large dimensions (~1 × 1 cm 2 ). VP also enhanced overall survival by about twofold when compared with V. Impressively, about 80% of animals treated with VP survived long term, beyond 150 days ( Fig. 4e ). To test immunological memory, the animals that survived from the first inoculation were rechallenged with the same E7-expressing TC-1 carcinoma after 6 months. All mice that were treated with either V or VP, and survived the first tumour inoculation, were completely tumour free after the rechallenge (Fig. 4e ). In a separate experiment, VP was evaluated against a traditionally formulated bolus vaccine. Consistent with previously reported findings, the bolus vaccine was partially effective and induced complete regression in only about 20% of the animals 9, 26 . In comparison, VP induced faster regression and about 80% of treated animals again showed complete regression ( Supplementary  Fig. 8a,b ). The anti-tumour effect of VP was antigen specific ( Fig. 4f ) and mediated by CD8 + T cells ( Fig. 4g, h) . Importantly, the therapeutic regression accomplished with just one immunization with VP was stronger than multiple treatments of conventionally adjuvanted E7 vaccines, and messenger RNA and nanoparticlebased technologies in similar tumour studies 9,27-29 . To further demonstrate that a direct association between the antigen and PEI in the vaccine is important, animals bearing established subcutaneous TC-1 tumours were treated with trans VP (E7 VP trans) and cis VP (E7 VP cis). Mice treated with cis VP showed superior tumour regression ( Supplementary Fig. 8c ), indicating that co-presentation of the antigens and PEI in the vaccine is probably a crucial component to generating anti-tumour immunity.
Finally, the MSR-PEI vaccine's ability to serve as a facile and effective platform for multiple neoantigens to induce tumour control was tested. First, VP demonstrated superior CTL response against B16F10 neoantigens in both tumour-free and tumour-bearing mice when compared with V ( Supplementary Figs. 9, 10 ). Next, 
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VP was evaluated in the highly aggressive and immune-suppressive B16F10 and CT26 models using combinations of neoantigen peptides 5 . As effector tumour-infiltrating lymphocytes (TILs) are needed to achieve tumour clearance 7 , the TIL population was isolated, directly stained and analysed on day 15 after inoculation, by which point some tumours in the untreated and V-treated animals had developed to the maximum allowed size. Impressively, tumours in VP-treated animals showed stronger enrichment in the IFN-γ + , TNF-α + and granzyme B + TILs (Fig. 5a, Supplementary Fig. 11 ). In contrast, V did not generate enhanced TIL response when compared with untreated animals. Lung metastases of B16F10 ( Fig. 5b ) and CT26 ( Supplementary Fig. 12 ) tumours were efficiently eradicated by one injection of VP containing a combination of B16 or CT26 neoantigens, respectively. Notably, these responses achieved with a single immunization of VP were comparable to those achieved with repeated immunizations of RNA-based neoantigen vaccines 5 . A standard prime and boost of VP improved subcutaneous B16F10 growth control ( Fig. 5c ) and induced temporary regression in a subset of the animals (Fig. 5d ). Checkpoint blockade therapies are effective in various types of cancer, but the response rate depends on a pre-existing immunity 30 . In this aggressive model, anti-CTLA4 therapy alone did not confer significant tumour growth control. However, one injection of VP in combination with anti-CTLA4 treatment significantly augmented the response (Fig. 5e ). This study describes a potentially transformative, simple and modular strategy to enhance antigen immunogenicity and drive effective anti-tumour immunity. This approach can effectively drive immune responses against libraries of cancer-specific mutations and synergize with other immunotherapies. The vaccine is assembled in less than 3 h by simple mixing of all components, and can in peripheral blood on day 7 after immunization with the MSR E7 vaccine (V) or the MSR-PEI E7 vaccine (VP) using 5 μ g or 20 μ g of B60K PEI, or left unimmunized (N) (n = 4, one-way ANOVA). c, ELISA analysis of TNF-α level in serum 24 h after vaccination with V or the MSR-PEI (B60K) vaccine (VP), or left unimmunized (N) (n = 4, compared with N by one-way ANOVA). d,e, Tumour growth (d) and overall survival (e) of mice bearing established E7-expressing TC-1 tumours (allowed to develop for 8 days) and treated with V or VP using L25K PEI, or left untreated (N), and subsequently rechallenged with TC-1 cells 6 months after the first inoculation (n = 10, compared with V by two-way ANOVA for d and by log-rank test for e). f, Overall survival of mice bearing established E7-expressing TC-1 tumours and treated with the MSR-PEI vaccine containing E7 (E7 VP) or the MSR-PEI vaccine containing SIINFEKL (SIINFEKL VP), or left untreated (Naive) (n = 8, compared with SIINFEKL VP by log-rank test). g, Flow cytometry analysis of blood T cells 3 days after treatment with a-CD8a monoclonal antibody (mab) or an isotype monoclonal antibody (representative data, repeated three times). h, Tumour growth of mice bearing established E7-expressing TC-1 tumours and treated with the MSR-PEI vaccine with either a-CD8a monoclonal antibody or an isotype monoclonal antibody (n = 8, compared with VP a-CD8 by two-way ANOVA). In a-c data depict mean ± s.d. and in d,h data depict mean ± s.e.m.
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be stored in a lyophilized form before or after antigens are added. Overall, this approach may have high value as a therapeutic multiantigen platform to enable robust personalized vaccination.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41563-018-0028-2. after inoculation in mice that received IV inoculation of B16F10 melanoma cells (allowed to develop for 1 day) and were treated with VP using L25K PEI and 50 μ g of the B16 neoantigens, or left untreated (N). Primary representative photographs of excised lungs are shown (n = 6, two-tailed t-test). c, Tumour growth in mice bearing established B16F10 tumours (allowed to develop for 3 days) and treated with two injections of VP using L25K PEI and 50 μ g of the B16 neoantigens on days 3 and 13, or left untreated (N) (n = 8, two-tailed t-test). d, Tumour volume change between days 13 and 17 after tumour inoculation (n = 8, two-tailed t-test). e, Tumour growth of mice bearing established B16F10 tumours (inoculated with 1 × 10 5 cells) and treated with anti-CTLA4 antibody (a-CTLA4), anti-CTLA4 antibody in combination with the MSR-PEI vaccine (VP + a-CTLA4) using L25K PEI and 50 μ g of the B16 neoantigens on day 5, or left untreated (N) (n = 8, *significant difference between VP + a-CTLA4 and a-CTLA4, ***significant difference between VP + a-CTLA4, ns between a-CTLA4 and N by one-way ANOVA). In a,b,d data depict mean ± s.d., in c,e data depict individual tumour growth.
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Methods
Materials, cell line and peptides. Branched 60K PEI (Sigma 181978), branched 2K PEI (Polysciences 06089), linear 25K PEI (Polysciences 23966) and linear 2K
PEI (Polysciences 24313) were diluted to 5.5 mg ml −1 in PBS, pH adjusted to 7.4 and stored away from direct light. Endotoxin-free OVA was used throughout the study (Invivogen, vac-pova). OVA was diluted to 5 mg ml −1 in endotoxin-free water. All antibodies were used according to the manufacturer's protocols. SIINFEKL and E7 49-57 tetramers were obtained from the Emory NIH Tetramer Core Facility. TC-1 cells were generated in the laboratory of T.-C. Wu (Johns Hopkins University, Baltimore, MD, USA, tested to be mycoplasma free) and maintained in RPMI supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin and 50 μ g ml −1 G418 24 . The TC-1 cells were tested to be mycoplasma-free and not further authenticated. B16F10 (ATCC) and CT26 cells (ATCC) were authenticated and tested to be mycoplasma-free by ATCC maintained in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin according to protocols from ATCC. Peptides used in this study are listed in Supplementary Table 4 . All murine peptides used in this study were synthesized to at least 95% purity from Peptide 2.0. All human neoantigen peptides were provided by Dr C. J. Wu (Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA). Peptides were first dissolved in DMSO to 50 mg ml −1 and further diluted in endotoxin-free water. Flow cytometry antibodies used in this study are listed in Supplementary Table 5 .
Vaccine formulations. MSRs were synthesized as described previously 13 . All vaccine components were incorporated after the MSRs were synthesized.
To formulate the MSR-PEI or cis MSR-PEI vaccine, 2 mg of the MSR (50 mg ml −1 working solution in PBS) was adsorbed with 100 μ g murine class B CpG-ODN (sequence TCCATGACGTTCCTGACGTT, IDT, 10 mg ml −1 working solution in dH 2 O) for 6-8 h at room temperature and subsequently lyophilized. The MSR (2 mg; 50 mg ml −1 working solution in PBS) was adsorbed with various doses (indicated in figure legends) of linear or branched PEI (in 100 μ l PBS, pH 7.4) at 37 °C for 15 min (MSR-PEI particles), and various doses of antigen (typically 100 μ g OVA or 50 μ g peptides) were adsorbed onto MSR-PEI particles for 1-3 h at 37 °C under shaking and subsequently lyophilized. Separately, 1 mg of the MSRs (50 mg ml −1 working solution in PBS) was loaded with 1 μ g murine GM-CSF (Peprotech, 1 mg ml −1 working solution) for 1 h at 37 °C under shaking. The MSR components (5 mg total) were combined and resuspended in cold PBS (150 μ l per vaccine) prior to immunization.
To formulate the trans MSR-PEI vaccines, 2 mg of the MSR (50 mg ml −1 working solution in PBS) was adsorbed with various doses of antigens (typically 100 μ g OVA or 50 μ g peptides) for 6-8 h at room temperature and subsequently lyophilized. 2 mg of the MSR (50 mg ml −1 working solution in PBS) was adsorbed with various doses (indicated in figure legends) of linear or branched PEI (in 100 μ l PBS, pH 7.4) at 37 °C for 15 min (MSR-PEI particles), and adsorbed with 100 μ g murine class B CpG-ODN (sequence TCCATGACGTTCCTGACGTT, IDT, 10 mg ml −1 working solution in dH 2 O) onto MSR-PEI particles for 1 h at 37 °C under shaking. Separately, 1 mg of the MSRs (50 mg ml −1 working solution in PBS) was loaded with 1 μ g murine GM-CSF (Peprotech) for 1 h at 37 °C under shaking. The MSR components (5 mg total) were combined and resuspended in cold PBS (150 μ l per vaccine) prior to immunization.
To prepare the MSR vaccines, 4 mg of the MSR (50 mg ml −1 working solution in PBS) was adsorbed with 100 μ g murine class B CpG-ODN (sequence TCCATGACGTTCCTGACGTT, IDT, 10 mg ml −1 working solution in dH 2 O) and the antigen (typically 100 μ g OVA or 50 μ g peptides) for 6-8 h at room temperature under shaking, and subsequently lyophilized. Separately, 1 mg of the MSRs (50 mg per ml working solution in PBS) were loaded with 1 μ g murine GM-CSF (Peprotech) for 1 h at 37 °C under shaking. The MSR components were combined and resuspended in cold PBS (150 μ l per vaccine) prior to immunization.
To prepare the bolus vaccine, 100 μ g murine class B CpG-ODN (sequence TCCATGACGTTCCTGACGTT, IDT, 10 mg ml −1 working solution in dH 2 O), 1 μ g murine GM-CSF and the antigen (typically 50 μ g peptides) were combined in 150 μ l cold PBS.
Vaccine components were tested to be endotoxin free (Charles River Laboratories) (Supplementary Table 2 ).
Animals. C57BL/6J and Balb/c mice were purchased from Jackson Laboratories and housed at Harvard University. Female mice between 6 weeks and 10 weeks old at the start of the experiments were used. All studies were carried outin accordance with institutional guidelines approved by Harvard University's Institutional Animal Care and Use Committee (IACUC) 31 .
Immunization. MSR vaccines were resuspended in 150 μ l of cold PBS immediately before injection. They were injected, via an 18 G needle, subcutaneously in the intrascapular region with the mouse under brief isoflurane anaesthesia.
Pore measurement. MSRs and MSR-PEI particles were first lyophilized. Nitrogen sorption isotherms of the particles were measured at 77 K using the ASAP 2000 system (Micromeritics). To determine the surface area of the particles, the Brunauer-Emmett-Teller method was used. To determine the pore size distributions, the Barret-Joyner-Hallenda model from the adsorption branch of the isotherm was used 31 .
Transmission electron microscopy (TEM).
To prepare the samples for TEM imaging, MSR and MSR-PEI particles were first diluted in 200-proof ethanol (Sigma-Aldrich) to about 0.1 mg ml −1 and briefly sonicated. An aliquot of 5-20 μ l of the diluted particles was dripped onto formvar/carbon TEM grids (Ted Pella) and dried at room temperature. The particles were imaged using the JEOL 2100 transmission electron microscope 31 .
Endotoxin measurement. Samples were analysed without dilution using EndoSafe cartridge kits (Charles River Laboratories, catalogue no. PTS55005F). Samples were assayed according to manufacturer protocols. Briefly, 25 μ l of sample was added to samples and control wells and the assay was run on an EndoSafe multi-cartridge system (Charles River Laboratories).
Incorporation efficiency assays.
To determine the incorporation efficiency of peptides onto the MSRs, 50 μ g of the indicated peptides was adsorbed onto 2 mg of MSRs or MSR-PEI particles overnight. The MSRs were centrifuged at 2,000g for 10 min to separate the unbound peptides from the bound peptides. Supernatant containing the unbound peptides was collected and the concentration of the peptides was quantified using micro-BCA (ThermoScientific). Quantification of peptide incorporation was confirmed using HPLC liquid chromatography-mass spectrometry (LC-MS) ( Supplementary Fig. 13a ). Incorporation efficiency was calculated as the total added to MSR minus the unbound portion. To ensure the accuracy of this approach, the bound peptides were dissociated from the MSRs with 40% Tween-20 under vigorous shaking for 4 h at room temperature. Subsequently, the concentrations of the peptides in the bound portion and the unbound portion were measured using LC-MS, and it was confirmed that nearly 100% of the peptides initially introduced to the particles were accounted for ( Supplementary Fig. 13b ).
To determine the incorporation efficiency of PEI onto the MSRs, PEI at the indicated doses was adsorbed onto MSR for 15 min at 37 °C. Subsequently, the MSRs were centrifuged at 2000g for 10 min to separate the bound PEI from the unbound PEI. Supernatant was collected and the concentration of PEI was measured using fluoraldehyde (Sigma-Aldrich). Incorporation efficiency was calculated as the total minus the unbound portion.
In vitro release studies. A 2 mg portion of MSRs was loaded with either 2 μ g of GM-CSF, 100 μ g of CpG or 10 μ g of rhodamine-PEI (L25K). The individual vaccine components were then resuspended in 1 ml of release medium, which is composed of RPMI (Sigma-Aldrich) supplemented with 1% penicillinstreptomycin and 10% heat-inactivated FBS (Sigma-Aldrich), in low-binding Eppendorf tubes. The release study was then carried out at 37 °C under gentle shaking. Periodically, supernatant containing the released component was collected by pelleting the particles at 2000g for 10 min. The release medium was subsequently replaced. For analysis, GM-CSF content was determined using ELISA (R&D). CpG content was detected using OliGreen (ThermoFisher) 13 .
BMDC differentiation, cytokine production and antigen presentation assays.
DCs were differentiated from bone marrow cells isolated from C57Bl/6J mice (Jackson Laboratories). Bone marrow was collected from the femur and tibia bones, and single-cell suspensions were cultured in RPMI (Sigma-Aldrich) supplemented with 10% heat-inactivated FBS (Sigma-Aldrich), 1% penicillinstreptomycin, 50 µ M β -mercaptoethanol and 20 ng ml −1 murine GM-CSF (Peprotech). Non-adherent and loosely adherent cells between days 7 and 10 of differentiation were collected and used for the studies. Differentiation was confirmed by staining the cells with anti-mouse CD11c and CD11b. To assess the uptake kinetics of PEI by BMDCs, 0.5 × 10 6 ml −1 immature BMDCs were plated onto non-tissue-culture-treated 12-well dishes and stimulated with 7 μ g of rhodamine-labelled L25K PEI for various lengths of time (0 h, 2 h, 6 h, 24 h, 72 h). BMDCs were harvested, resuspended in FACS buffer and the rhodamine signal analsed using flow cytometry (BD Biosciences). To assess the BMDCs' activity after PEI stimulation, 1 × 10 6 ml −1 immature BMDCs were plated onto tissue-culture-treated 12-well dishes and stimulated with various doses of L25K or B60K PEI or MSR-PEI for 24 h, in either the presence or absence of 20 ng ml −1 lipopolysaccharide. BMDCs were harvested, resuspended in FACS buffer and stained with 7-AAD (eBioscience), anti-CD11c, anti-CD86 and anti-MHCII for 15 min on ice. BMDCs were then washed in FACS buffer and analysed using flow cytometry. Separately, supernatant was collected and analysed for IL-1β , IL-6, TNF-α and IFN-γ using ELISA according to the manufacturer's protocols (eBioscience). To assess BMDC cross-presentation, 0.5 × 10 6 ml −1 BMDCs were pulsed with 20 μ g OVA (Invivogen) either alone or in the presence of 5 μ g or 10 μ g B60K PEI for 48 h. BMDCs were then harvested and stained using 7-AAD (Biolegend), anti-CD11c and anti-SIINFEKL/H-2Kb for 15 min on ice, washed and analysed using flow cytometry (LSRFortessa, BD) 32 .
Lysosomal rupture in BMDCs. Immature BMDCs (1 × 10 6 ml −1 ) were plated onto tissue-culture-treated 12-well dishes. BMDCs were stimulated with 40 μ g of Letters NATuRE MATERIALS MSRs, 40 μ g of MSR-PEI particles (12.5 μ g of L25K-PEI per mg MSRs) or 2 μ g free PEI (L25K) for 24 h. Subsequently, BMDCs were incubated with acridine orange (ThermoFisher, diluted 1:20,000) for 4 h. Acridine orange signal was assessed using flow cytometry at 488 nm (excitation) and 650-690 nm (emission) (LSRFortessa, BD) 21 .
TLR-4 neutralization. 1 × 10 6 ml −1 immature BMDCs were plated onto tissueculture-treated 12-well dishes and treated with TLR4 (CD284)/MD2 monoclonal antibody (Biolegend, clone MTS510) for 1 h at 37 °C. Subsequently, the BMDCs were stimulated with 40 μ g of MSR or MSR-PEI particles (12.5 μ g PEI per mg MSRs) for 24 h. BMDCs were collected, stained with anti-CD11c, anti-CD86 and 7AAD, and analysed using flow cytometry (LSRFortessa, BD).
Therapeutic tumour studies. Cells were used at passage number 5 or earlier and passaged at least twice prior to inoculation. In the subcutaneous therapeutic TC-1 model, female C57BL/6 mice were injected with a single-cell suspension of 2 × 10 5 TC-1 cells in 100 μ l cold PBS in the back of the neck on day 0. In the subcutaneous therapeutic B16F10 model, female C57BL/6 mice were injected with a single-cell suspension of 1 × 10 5 B16F10 cells in 100 μ l cold PBS in the back of the neck on day 0. Mice were immunized on indicated days, and tumour area was monitored using a calliper: longest surface length (a) and width (b), and the tumour size was expressed as area (ab). Mice were killed when the longest side reached 2 cm or according to IACUC standards. In the therapeutic B16F10 or CT26 lung metastasis model, mice were injected intravenously with 2 × 10 5 B16F10 or CT26 cells in 100 μ l cold PBS on day 0. Lungs were excised on day 16 and fixed in Fekete's solution. Lung metastasis nodules were then manually enumerated. For anti-CTLA4 therapies, 100 μ g per mouse of anti-mouse CTLA-4 antibodies (BioXcell, clone 9D9) were administered intraperitoneally on days 1, 3, 6 and 9 after tumour inoculation.
CD8 + T-cell depletion. CD8 + T cells were depleted by injecting 100 μ g of anti-CD8a monoclonal antibody (BioXCell, clone 2.43) intraperitoneally twice weekly, starting the day before vaccination 33 . Depletion was confirmed using flow cytometry.
Scaffold explant and analysis. Scaffold tissues were surgically removed from the animals after euthanasia. They were first processed using mechanical disruption, and subsequently digested in 250 U ml −1 collagenase IV (Worthington) in RPMI for 30 min. at 37 °C under gentle shaking. Cell and tissue suspensions were filtered through a 40 μ m cell strainer to separate single cells from large MSR particles. The cells and small remaining MSR particles were pelleted, washed three times and counted manually using a haemocytometer. Dead cells were visualized using trypan blue (ThermoFisher). Subsequently, cells were stained with anti-mouse CD11c, CD86, CCR7 and SIINFEKL/H-2K b monoclonal antibodies in FACS buffer (PBS supplemented with 1% BSA and 0.1% sodium azide) for 15 min on ice. Dead cells and MSR particles were stained and excluded from analysis using 7-AAD (eBioscience) or a fixable viability dye (eBioscience). Finally, cells were washed three times in FACS buffer and analysed using flow cytometry (LSRFortessa, BD) 13 .
Lymph node analysis. Vaccine dLNs were surgically removed from the animals. They were then processed through mechanical disruption and digested for 30 min at 37 °C in RPMI containing 0.5 mg ml −1 collagenase 4 and 0.1 mg ml −1 DNAse. Cells were then filtered through a 40 μ m cell and washed in cold PBS. Single-cell suspensions were enumerated (Beckman-Coulter) and stained with an Alexa Fluor 780 dead exclusion dye (eBioscience), anti-mouse CD11c, CD11b, CD86, MHC-II and F4/80 for 15 min on ice. DQ-OVA was visualized in the FITC channel. The cells were then washed and analysed using flow cytometry (LSRFortessa, BD).
Tetramer analysis and peptide restimulation of circulating PBMCs.
About 100 μ l of peripheral blood was collected into heparin-coated tubes (BD) and kept on ice. Red blood cells (RBCs) were removed by adding 1 ml RBC lysis buffer (BioLegend) for 1 min at room temperature; lysis was quenched by adding 9 ml cold PBS directly. Cells were pelleted and washed in FACS staining buffer. To carry out tetramer staining, blood cells were incubated with 50 μ l of 7 μ g ml −1 Alexa Fluor 647 conjugated peptide-MHC tetramers (NIH Tetramer Core) for 20 min at 37 °C. Subsequently, cells were pelleted and stained with 7-AAD, anti-mouse CD3e and CD8a for 15 mins on ice. Finally, cells were washed three times in FACS staining buffer and analysed using flow cytometry (LSRFortessa). To carry out peptide restimulation, blood cells were pulsed with 2 μ g ml −1 of various MHC-I restricted peptides for 1-1.5 h at 37 °C in T-cell medium (RPMI supplemented with 110 mg l −1 sodium pyruvate, 5 mM HEPES, 50 μ M β -mercaptoethanol, 10% heatinactivated FBS and 1% penicillin-streptomycin). Subsequently, cytokine secretion was stopped by directly adding Golgi Plug (Biolegend) to the culture. Cells were cultured for another 4 h at 37 °C. Cells were pelleted and stained with Alexa Fluor 780 dead exclusion dye, anti-mouse CD3e, CD8a and CD4 for 15 min on ice. Cells were then fixed and permeabilized (eBioscience 88-8824-00), and stained with anti-mouse IFN-γ for 30 min at 4 °C. Finally, cells were washed and analysed using flow cytometry (LSRFortessa, BD).
Peptide restimulation of splenic CD8 + T cells. To isolate splenic DCs, naïve spleens were retrieved and digested in RPMI supplemented with 1 mg ml −1 collagenase 4 (Worthington) and 0.1 mg ml −1 DNase (New England Biolabs) for 30 min at 37 °C. RBCs were lysed using RBC lysis buffer (Biolegend). Dead cells were removed (Miltenyi Biotec), and splenic DCs were obtained using a CD11c + magnetic sorting kit (Miltenyi Biotec). DCs were pulsed with 5 μ g ml −1 of M27, M30 or a control peptide. Separately, spleens from vaccinated mice were retrieved (8 days after vaccination). Splenocytes were isolated from the spleens by physically grinding the spleens on a cell filtration device in RPMI supplemented with 2% FBS. RBCs were lysed and CD8 + or CD4 + T cells were then obtained using a negative CD8 + or CD4 + T-cell selection kit (Miltenyi Biotec). The sorted T cells were labelled with CFSE (ThermoFisher). T cells and DCs were cultured together at a 10:1 (T:DC) ratio for 3 days at 37 °C to allow for antigen-specific T-cell proliferation. On day 3, cytokine secretion was stopped by incubating with Golgi Plug (Biolegend) for 4 h at 37 °C. Subsequently, cells were collected and stained with Alexa Fluor 780 dead exclusion dye, anti-mouse CD3e, CD8a and CD4 for 15 min on ice before fixing and permeabilizing (eBioscience 88-8824-00). Cells were then stained with anti-mouse IFN-γ for 30 min at 4 °C and analysed using flow cytometry (LSRFortessa, BD) 5,34 . TIL analysis. Tumours were explanted and cut into small pieces in 5 ml of RPM. The samples were then digested in 15 ml RPMI supplemented with 2% FCS, 50 U ml −1 collagenase IV (Invitrogen), 100 μ g ml −1 hyaluronidase and 20 U ml −1 DNase (Roche) for 2 h at 37 °C using gentleMACS dissociators (Miltenyi Biotech). Suspensions were filtered through a 40 µ M strainer and washed three times with PBS. Lymphocyte population was enriched through gradient centrifugation at 50g for 5 min, repeated three times. Supernatant was collected and stained with a Zombie-UV dead exclusion dye, anti-mouse CD45, CD3e, CD4, CD8a, CD62L and CD44 for 15 min on ice before fixing and permeabilizing (eBioscience 00-5523-00). Cells were then stained with anti-mouse IFN-γ , TNF-α and granzyme B for 30 min at 4 °C and analysed using flow cytometry (LSRFortessa, BD) 35 .
Statistical analysis.
All values in the present study are expressed as mean ± s.d. unless otherwise indicated in the figure legends. Statistical analysis was performed using GraphPad Prism. The significance between two groups was analysed by a two-tailed Student t-test. Sample variance was tested using the F-test. For multiple comparisons, a one-way or a two-way ANOVA test was used. In all cases, a P value of less than 0.05 was considered significant. Details for statistical analyses for each comparison are reported in Supplementary Table 6 .
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary.
Data availability. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Corresponding author(s): David Mooney
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Describe whether the experimental findings were reliably reproduced.
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Randomization
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